Non-canonical anchor motif peptides bound to MHC class I induce cellular responses

Molecular Immunology

Volumn 46, Issue 6, 2009, Pages 1171-1178

  Lazoura, Eliada ^a   Lodding, Jodie ^a   Farrugia, William ^a   Day, Stephanie ^a   Ramsland, Paul A ^a   Apostolopoulos, Vasso ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

E pocket; H2Kb; MHC class I; Non canonical anchor motif peptides; Streptococcus; Strp9; Vaccine design; YEA9; Yeastolate

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN STRP9; PROTEIN YEA9; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN STRUCTURE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; FEMALE; HYDROGEN BOND; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HYDROGEN BONDING; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEIN CONFORMATION; RECEPTORS, ANTIGEN, T-CELL;

STREPTOCOCCUS;

EID: 60949084198     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.11.007     Document Type: Article

References (60)

1. Apostolopoulos V., Chelvanayagam G., Xing P.X., and McKenzie I.F. Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules. J. Immunol. 161 (1998) 767-775
2. Apostolopoulos V., Haurum J.S., and McKenzie I.F. MUC1 peptide epitopes associated with five different H2 class I molecules. Eur. J. Immunol. 27 (1997) 2579-2587
3. Apostolopoulos V., Karanikas V., Haurum J.S., and McKenzie I.F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159 (1997) 5211-5218
4. Apostolopoulos V., and Lazoura E. Noncanonical peptides in complex with MHC class I. Expert Rev. Vaccines 3 (2004) 151-162
5. Apostolopoulos V., Matsoukas J., Plebanski M., and Mavromoustakos T. Applications of peptide mimetics in cancer. Curr. Med. Chem. 9 (2002) 411-420
6. Apostolopoulos V., and McKenzie I.F. Cellular mucins: targets for immunotherapy. Crit. Rev. Immunol. 14 (1994) 293-309
7. Apostolopoulos V., McKenzie I.F., and Pietersz G.A. Breast cancer immunotherapy: current status and future prospects. Immunol. Cell Biol. 74 (1996) 457-464
8. Apostolopoulos V., McKenzie I.F., and Wilson I.A. Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design. Front Biosci. 6 (2001) D1311-D1320
9. Apostolopoulos V., Yu M., Corper A.L., Li W., McKenzie I.F., Teyton L., Wilson I.A., and Plebanski M. Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J. Mol. Biol. 318 (2002) 1307-1316
10. Apostolopoulos V., Yu M., Corper A.L., Teyton L., Pietersz G.A., McKenzie I.F., Wilson I.A., and Plebanski M. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J. Mol. Biol. 318 (2002) 1293-1305
11. Apostolopoulos V., Yu M., McKenzie I.F., and Wilson I.A. Structural implications for the design of molecular vaccines. Curr. Opin. Mol. Ther. 2 (2000) 29-36
12. Apostolopoulos V., Yuriev E., Ramsland P.A., Halton J., Osinski C., Li W., Plebanski M., Paulsen H., and McKenzie I.F. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15029-15034
13. Balendiran G.K., Solheim J.C., Young A.C., Hansen T.H., Nathenson S.G., and Sacchettini J.C. The three-dimensional structure of an H2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 6880-6885
14. Burrows J.M., Bell M.J., Brennan R., Miles J.J., Khanna R., and Burrows S.R. Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition. Mol. Immunol. 45 (2008) 1818-1824
15. Burrows S.R., Rossjohn J., and McCluskey J. Have we cut ourselves too short in mapping CTL epitopes?. Trends Immunol. 27 (2006) 11-16
16. Carbone F.R., and Bevan M.J. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J. Exp. Med. 169 (1989) 603-612
17. Chelvanayagam G., Apostolopoulos V., and McKenzie I.F. Milestones in the molecular structure of the major histocompatibility complex. Protein Eng. 10 (1997) 471-474
18. Daser A., Urlaub H., and Henklein P. HLA-B27 binding peptides derived from the 57 kDa heat shock protein of Chlamydia trachomatis: novel insights into the peptide binding rules. Mol. Immunol. 31 (1994) 331-336
19. Degano M., Garcia K.C., Apostolopoulos V., Rudolph M.G., Teyton L., and Wilson I.A. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 12 (2000) 251-261
20. Eisen H.N., Sykulev Y., and Tsomides T.J. Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Adv. Protein Chem. 49 (1996) 1-56
21. Falk K., Rotzschke O., Stevanovic S., Jung G., and Rammensee H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351 (1991) 290-296
22. Franco M.A., Lefevre P., Willems P., Tosser G., Lintermanns P., and Cohen J. Identification of cytotoxic T cell epitopes on the VP3 and VP6 rotavirus proteins. J. Gen. Virol. 75 Pt 3 (1994) 589-596
23. Fremont D.H., Matsumura M., Stura E.A., Peterson P.A., and Wilson I.A. Crystal structures of two viral peptides in complex with murine MHC class I H2Kb. Science 257 (1992) 919-927
24. Fremont D.H., Stura E.A., Matsumura M., Peterson P.A., and Wilson I.A. Crystal structure of an H2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2479-2483
25. Gao L., Walter J., Travers P., Stauss H., and Chain B.M. Tumor-associated E6 protein of human papillomavirus type 16 contains an unusual H2Kb-restricted cytotoxic T cell epitope. J. Immunol. 155 (1995) 5519-5526
26. Garcia K.C., Degano M., Pease L.R., Huang M., Peterson P.A., Teyton L., and Wilson I.A. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 279 (1998) 1166-1172
27. Gillanders W.E., Hanson H.L., Rubocki R.J., Hansen T.H., and Connolly J.M. Class I-restricted cytotoxic T cell recognition of split peptide ligands. Int. Immunol. 9 (1997) 81-89
28. Glithero A., Tormo J., Haurum J.S., Arsequell G., Valencia G., Edwards J., Springer S., Townsend A., Pao Y.L., Wormald M., Dwek R.A., Jones E.Y., and Elliott T. Crystal structures of two H2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity 10 (1999) 63-74
29. Haurum J.S., Tan L., Arsequell G., Frodsham P., Lellouch A.C., Moss P.A., Dwek R.A., McMichael A.J., and Elliott T. Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. Eur. J. Immunol. 25 (1995) 3270-3276
30. Jackson M.R., Song E.S., Yang Y., and Peterson P.A. Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 12117-12121
31. Jameson S.C., and Bevan M.J. Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a Kb-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs. Eur. J. Immunol. 22 (1992) 2663-2667
32. Kast W.M., Roux L., Curren J., Blom H.J., Voordouw A.C., Meloen R.H., Kolakofsky D., and Melief C.J. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2283-2287
33. Kellenberger C., Roussel A., and Malissen B. The H2Kk MHC peptide-binding groove anchors the backbone of an octameric antigenic peptide in an unprecedented mode. J. Immunol. 175 (2005) 3819-3825
34. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Drijfhout J.W., Wafelman A.R., Oostendorp J., Fleuren G.J., Offringa R., van der Burg S.H., and Melief C.J. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14 (2008) 169-177
35. Lazoura E., and Apostolopoulos V. Insights into peptide-based vaccine design for cancer immunotherapy. Curr. Med. Chem. 12 (2005) 1481-1494
36. Lazoura E., and Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr. Med. Chem. 12 (2005) 629-639
37. Lazoura E., Lodding J., Farrugia W., Ramsland P.A., Stevens J., Wilson I.A., Pietersz G.A., and Apostolopoulos V. Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology 119 (2006) 306-316
38. Mandelboim O., Bar-Haim E., Vadai E., Fridkin M., and Eisenbach L. Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas. J. Immunol. 159 (1997) 6030-6036
39. Matsumura M., Fremont D.H., Peterson P.A., and Wilson I.A. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 257 (1992) 927-934
40. Matsumura M., Saito Y., Jackson M.R., Song E.S., and Peterson P.A. In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells. J. Biol. Chem. 267 (1992) 23589-23595
41. Meijers R., Lai C.C., Yang Y., Liu J.H., Zhong W., Wang J.H., and Reinherz E.L. Crystal structures of murine MHC Class I H2 D(b) and K(b) molecules in complex with CTL epitopes from influenza A virus: implications for TCR repertoire selection and immunodominance. J. Mol. Biol. 345 (2005) 1099-1110
42. Molano A., Erdjument-Bromage H., Fremont D.H., Messaoudi I., Tempst P., and Nikolic-Zugic J. Peptide selection by an MHC H2Kb class I molecule devoid of the central anchor ("C") pocket. J. Immunol. 160 (1998) 2815-2823
43. Ostrov D.A., Roden M.M., Shi W., Palmieri E., Christianson G.J., Mendoza L., Villaflor G., Tilley D., Shastri N., Grey H., Almo S.C., Roopenian D., and Nathenson S.G. How H13 histocompatibility peptides differing by a single methyl group and lacking conventional MHC binding anchor motifs determine self-nonself discrimination. J. Immunol. 168 (2002) 283-289
44. Petrone P.M., and Garcia A.E. MHC-peptide binding is assisted by bound water molecules. J. Mol. Biol. 338 (2004) 419-435
45. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., and Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50 (1999) 213-219
46. Rammensee H.G. Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7 (1995) 85-96
47. Rammensee H.G., Friede T., and Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 41 (1995) 178-228
48. Reddehase M.J., Rothbard J.B., and Koszinowski U.H. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 337 (1989) 651-653
49. Saito Y., Peterson P.A., and Matsumura M. Quantitation of peptide anchor residue contributions to class I major histocompatibility complex molecule binding. J. Biol. Chem. 268 (1993) 21309-21317
50. Speir J.A., Garcia K.C., Brunmark A., Degano M., Peterson P.A., Teyton L., and Wilson I.A. Structural basis of 2C TCR allorecognition of H2Ld peptide complexes. Immunity 8 (1998) 553-562
51. Stura E.A., Matsumura M., Fremont D.H., Saito Y., Peterson P.A., and Wilson I.A. Crystallization of murine major histocompatibility complex class I H2Kb with single peptides. J. Mol. Biol. 228 (1992) 975-982
52. Sykulev Y., Vugmeyster Y., Brunmark A., Ploegh H.L., and Eisen H.N. Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Immunity 9 (1998) 475-483
53. Tallquist M.D., Yun T.J., and Pease L.R. A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity. J. Exp. Med. 184 (1996) 1017-1026
54. Tirosh B., el-Shami K., Vaisman N., Carmon L., Bar-Haim E., Vadai E., Feldman M., Fridkin M., and Eisenbach L. Immunogenicity of H2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunol. Lett. 70 (1999) 21-28
55. Udaka K., Wiesmuller K.H., Kienle S., Jung G., and Walden P. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157 (1996) 670-678
56. Van Bleek G.M., and Nathenson S.G. Isolation of an endogenously processed immunodominant viral peptide from the class I H2Kb molecule. Nature 348 (1990) 213-216
57. Welters M.J., Kenter G.G., Piersma S.J., Vloon A.P., Lowik M.J., Berends-van der Meer D.M., Drijfhout J.W., Valentijn A.R., Wafelman A.R., Oostendorp J., Fleuren G.J., Offringa R., Melief C.J., and van der Burg S.H. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14 (2008) 178-187
58. Young A.C., Zhang W., Sacchettini J.C., and Nathenson S.G. The three-dimensional structure of H2Db at 2.4 A resolution: implications for antigen-determinant selection. Cell 76 (1994) 39-50
59. Zhang W., Young A.C., Imarai M., Nathenson S.G., and Sacchettini J.C. Crystal structure of the major histocompatibility complex class I H2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 8403-8407
60. Zinkernagel R.M., and Doherty P.C. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27 (1979) 51-177